HEADER APOPTOSIS 01-NOV-00 1G5M TITLE HUMAN BCL-2, ISOFORM 1 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEIN (APOPTOSIS REGULATOR BCL-2 WITH PUTATIVE FLEXIBLE COMPND 3 LOOP REPLACED WITH A PORTION OF APOPTOSIS REGULATOR BCL-X PROTEIN); COMPND 4 CHAIN: A; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS APOPTOSIS EXPDTA SOLUTION NMR AUTHOR A.M.PETROS,A.MEDEK,D.G.NETTESHEIM,D.H.KIM,H.S.YOON,K.SWIFT, AUTHOR 2 E.D.MATAYOSHI,T.OLTERSDORF,S.W.FESIK REVDAT 4 21-DEC-22 1G5M 1 SEQADV REVDAT 3 23-FEB-22 1G5M 1 REMARK REVDAT 2 24-FEB-09 1G5M 1 VERSN REVDAT 1 21-MAR-01 1G5M 0 JRNL AUTH A.M.PETROS,A.MEDEK,D.G.NETTESHEIM,D.H.KIM,H.S.YOON,K.SWIFT, JRNL AUTH 2 E.D.MATAYOSHI,T.OLTERSDORF,S.W.FESIK JRNL TITL SOLUTION STRUCTURE OF THE ANTIAPOPTOTIC PROTEIN BCL-2. JRNL REF PROC.NATL.ACAD.SCI.USA V. 98 3012 2001 JRNL REFN ISSN 0027-8424 JRNL PMID 11248023 JRNL DOI 10.1073/PNAS.041619798 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH Y.TSUJIMOTO,C.M.CROCE REMARK 1 TITL ANALYSIS OF THE STRUCTURE, TRANSCRIPTS, AND PRODUCTS OF REMARK 1 TITL 2 BCL-2, THE GENE INVOLVED IN HUMAN FOLLICULAR LYMPHOMA REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 83 5214 1986 REMARK 1 REFN ISSN 0027-8424 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2000 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1G5M COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 20-NOV-00. REMARK 100 THE DEPOSITION ID IS D_1000012262. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 298 REMARK 210 PH : 7.8 REMARK 210 IONIC STRENGTH : 20 MM REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 15N-BCL-2(1); 15N,13C-BCL-2(1); REMARK 210 15N,13C-BCL-2(1) REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 3D_15N-SEPARATED_NOESY; 3D_13C REMARK 210 -SEPARATED_NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 800 MHZ; 600 MHZ; 500 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NULL REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : NULL REMARK 210 CONFORMERS, NUMBER SUBMITTED : 1 REMARK 210 CONFORMERS, SELECTION CRITERIA : NULL REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : NULL REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 465 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 RES C SSSEQI REMARK 465 MET A 1 REMARK 465 ALA A 2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A 4 -78.91 65.43 REMARK 500 ARG A 6 126.26 -179.88 REMARK 500 THR A 7 58.70 -177.52 REMARK 500 ASP A 10 62.91 63.13 REMARK 500 TYR A 28 106.11 -47.21 REMARK 500 TRP A 30 -66.27 -96.38 REMARK 500 ALA A 32 -58.70 75.77 REMARK 500 VAL A 36 107.83 178.95 REMARK 500 PRO A 44 82.04 -59.75 REMARK 500 SER A 49 38.10 -147.25 REMARK 500 TYR A 108 -70.05 -78.95 REMARK 500 PHE A 112 -84.95 68.54 REMARK 500 HIS A 120 -123.10 -67.38 REMARK 500 LEU A 121 98.07 179.06 REMARK 500 THR A 122 164.50 167.37 REMARK 500 THR A 125 -56.22 -128.17 REMARK 500 ASP A 140 76.38 -106.95 REMARK 500 ARG A 183 -73.51 -65.89 REMARK 500 PRO A 204 -158.80 -57.86 REMARK 500 SER A 205 79.10 -118.26 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1BXL RELATED DB: PDB REMARK 900 STRUCTURE OF BCL-XL/BAK PEPTIDE COMPLEX, NMR, MINIMIZED AVERAGE REMARK 900 STRUCTURE REMARK 900 RELATED ID: 1G5J RELATED DB: PDB REMARK 900 COMPLEX OF BCL-XL WITH PEPTIDE FROM BAD REMARK 900 RELATED ID: 1G5O RELATED DB: PDB REMARK 900 HUMAN BCL-2, ISOFORM 2 DBREF 1G5M A 1 34 UNP P10415 BCL2_HUMAN 1 34 DBREF 1G5M A 35 50 UNP Q07817 BCLX_HUMAN 29 44 DBREF 1G5M A 92 207 UNP P10415 BCL2_HUMAN 92 207 SEQADV 1G5M ALA A 96 UNP P10415 THR 96 VARIANT SEQADV 1G5M GLY A 110 UNP P10415 ARG 110 VARIANT SEQRES 1 A 166 MET ALA HIS ALA GLY ARG THR GLY TYR ASP ASN ARG GLU SEQRES 2 A 166 ILE VAL MET LYS TYR ILE HIS TYR LYS LEU SER GLN ARG SEQRES 3 A 166 GLY TYR GLU TRP ASP ALA GLY ASP ASP VAL GLU GLU ASN SEQRES 4 A 166 ARG THR GLU ALA PRO GLU GLY THR GLU SER GLU VAL VAL SEQRES 5 A 166 HIS LEU ALA LEU ARG GLN ALA GLY ASP ASP PHE SER ARG SEQRES 6 A 166 ARG TYR ARG GLY ASP PHE ALA GLU MET SER SER GLN LEU SEQRES 7 A 166 HIS LEU THR PRO PHE THR ALA ARG GLY ARG PHE ALA THR SEQRES 8 A 166 VAL VAL GLU GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY SEQRES 9 A 166 ARG ILE VAL ALA PHE PHE GLU PHE GLY GLY VAL MET CYS SEQRES 10 A 166 VAL GLU SER VAL ASN ARG GLU MET SER PRO LEU VAL ASP SEQRES 11 A 166 ASN ILE ALA LEU TRP MET THR GLU TYR LEU ASN ARG HIS SEQRES 12 A 166 LEU HIS THR TRP ILE GLN ASP ASN GLY GLY TRP ASP ALA SEQRES 13 A 166 PHE VAL GLU LEU TYR GLY PRO SER MET ARG HELIX 1 1 ASP A 10 GLN A 25 1 16 HELIX 2 2 VAL A 92 ARG A 109 1 18 HELIX 3 3 ALA A 113 GLN A 118 5 6 HELIX 4 4 THR A 122 PHE A 138 1 17 HELIX 5 5 ASN A 143 ARG A 164 1 22 HELIX 6 6 MET A 166 HIS A 184 1 19 HELIX 7 7 HIS A 184 GLY A 193 1 10 HELIX 8 8 GLY A 194 GLY A 203 1 10 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000